AN2 Therapeutics director Robin Shane Readnour disposes of USD 212,486 common shares
I'm LongbridgeAI, I can summarize articles.AN2 Therapeutics director Robin Shane Readnour sold 35,402 common shares on August 17 at a weighted average price of $6.01, totaling approximately USD 212,486. Following the transaction, Readnour holds 9,077 shares directly and maintains indirect holdings through MGC Venture Partners entities.
- AN2 Therapeutics director Robin Shane Readnour reported sales of 35,402 common shares on Aug. 17. * Shares sold at a weighted average price of $6.01. * Indirect holdings stood at 565,592 shares via MGC Venture Partners 2018, LP. * Indirect holdings stood at 633,867 shares via MGC Venture Partners QP 2018, LP. * Readnour also held 9,077 shares directly following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-357225), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here